OptiNose (OPTN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OptiNose (OPTN) has a cash flow conversion efficiency ratio of -0.027x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.67 Million) by net assets ($-61.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OptiNose - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how OptiNose's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OptiNose (OPTN) total liabilities for a breakdown of total debt and financial obligations.
OptiNose Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OptiNose ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Takisawa Technology Co Ltd
TWO:6609
|
0.047x |
|
New Delhi Television Limited
NSE:NDTV
|
1.199x |
|
GIIR Inc
KO:035000
|
0.007x |
|
Company K Partners Limited
KQ:307930
|
-0.012x |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLACF
|
-0.003x |
|
GEA Grenobl. Elect.
PA:GEA
|
0.134x |
|
Stella Holdings Bhd
KLSE:5006
|
-0.011x |
|
Chariot Oil & Gas Limited
F:C62
|
-0.033x |
Annual Cash Flow Conversion Efficiency for OptiNose (2015–2024)
The table below shows the annual cash flow conversion efficiency of OptiNose from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see OPTN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-40.36 Million | $-44.89 Million | 1.112x | +369.11% |
| 2023-12-31 | $-86.61 Million | $-20.53 Million | 0.237x | -80.16% |
| 2022-12-31 | $-56.62 Million | $-67.65 Million | 1.195x | -66.19% |
| 2021-12-31 | $-21.77 Million | $-76.94 Million | 3.534x | +127.82% |
| 2020-12-31 | $6.79 Million | $-86.21 Million | -12.700x | -761.19% |
| 2019-12-31 | $61.58 Million | $-90.81 Million | -1.475x | -90.50% |
| 2018-12-31 | $118.61 Million | $-91.82 Million | -0.774x | -235.46% |
| 2017-12-31 | $154.50 Million | $-35.65 Million | -0.231x | +95.92% |
| 2016-12-31 | $-3.84 Million | $21.72 Million | -5.659x | -635.04% |
| 2015-12-31 | $-27.15 Million | $-28.71 Million | 1.058x | -- |
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more